Darlene Dobkowski, Managing Editor for CURE® magazine, has been with the team since October 2020 and has covered health care in other specialties before joining MJH Life Sciences. She graduated from Emerson College with a Master’s degree in print and multimedia journalism. In her free time, she enjoys buying stuff she doesn’t need from flea markets, taking her dog everywhere and scoffing at decaf.
Savoring Every Ounce of Life While Undergoing Treatment for Skin Cancer
January 14th 2021In this episode of the “CURE Talks Cancer” podcast, we spoke with someone who has undergone 41 surgeries and physically debilitating treatments during his more than 15-year journey with several cases of skin cancer. We discussed his cancer journey, and why, as he starts a new treatment after his most prior therapy failed, he’s focused on quality rather than quantity of life.
Novel Drug with Dexamethasone Safe in Heavily Pretreated Multiple Myeloma
January 13th 2021Melflufen with dexamethasone was an effective treatment option for patients with relapsed or refractory multiple myeloma previously treated with a specific chemotherapy drug and/or an anti-CD38 monoclonal antibody.
Bristol-Myers Squibb Pulls Small Cell Lung Cancer Indication for Opdivo
January 4th 2021The company has withdrawn the small cell lung cancer indication for Opdivo (nivolumab) based on discussions with the FDA, particularly focused on post-market studies that missed their primary endpoints of overall survival.
COVID-19 Pandemic May Impact Clinical Trial Enrollment Due to Increased Exposure to the Virus
January 4th 2021In participants who reported that the pandemic negatively impacted their decision to enroll in a clinical trial, some of the most common reasons included exposure to the virus and limited access to care.
Communication With the Treatment Team, Self-Advocacy Play Important Roles in Small Cell Lung Cancer
January 2nd 2021In an interview with CURE®, Dr. Wade T. Iams discussed small cell lung cancer, a subtype of lung cancer that starts from neuroendocrine cells in the lung, how different stages are treated and the potential benefits of having a treatment team to communicate with every step of the way.
Clinical Trials on Smoldering Myeloma May Open Doors to More Precision Medicine
December 29th 2020In an interview with CURE®, Dr. Irene M. Ghobrial discussed smoldering myeloma, a precursor condition that may progress to multiple myeloma, how to proceed if diagnosed with the condition and the available opportunities to participate in clinical trials to learn more.
FDA Approves Tagrisso as Adjuvant Therapy for Non-Small Cell Lung Cancer After Tumor Resection
December 18th 2020This approval allows Tagrisso to be used after tumor resection in non-small cell lung cancer patients with tumors that have certain epidermal growth factor receptor mutations or deletions.
FDA Approves Xpovio for Use with Velcade and Dexamethasone in Multiple Myeloma
December 18th 2020This treatment regimen of Xpovio with Velcade, approved for patients with multiple myeloma previously treated with at least one therapy, provides another option for patients with multiple myeloma to potentially close the treatment gap.
Dietary Changes to Reduce Diabetes Risk May Also Increase Survival for Breast Cancer
December 10th 2020Women with higher diet adherence scores after diagnosis had a 33% lower risk for all-cause mortality and a 17% lower risk for mortality related to breast cancer compared with women with lower diet adherence scores.